BrainStorm CEO to Provide Company Update at the BIO CEO & Investor Conference
February 04, 2020 04:45 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Feb. 04, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of autologous cellular therapies for highly debilitating neurodegenerative diseases,...
BrainStorm Issues 2019 Letter to Shareholders
December 18, 2019 05:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapeutics for neurodegenerative diseases, today issued a Letter to...
BrainStorm Selected as Buzz of BIO 2020 Winner
December 11, 2019 05:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
Suun kautta annosteltavan levosimendaanin tutkimustuloksia esiteltiin kansainvälisessä ALS/MND symposiumissa
December 09, 2019 03:15 ET
|
Orion Oyj
ORION OYJ LEHDISTÖTIEDOTE 9.12.2019 klo 10.15 Orion on tutkinut suun kautta annosteltavan levosimendaanin vaikutusta ALS-potilaiden...
Orion presented data on oral levosimendan at the 30th International Symposium on ALS/MND
December 09, 2019 03:15 ET
|
Orion Oyj
Orion Corporation Press release 9 December at 10.15 EET Orion has studied the effects of oral levosimendan on respiratory function in patients...
Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)
December 04, 2019 08:00 ET
|
Seelos Therapeutics, Inc.
NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
AZTherapies Announces Publication of Data Supporting the Targeting of Neuroinflammation in the Treatment of ALS in Scientific Reports
December 03, 2019 08:32 ET
|
AZTherapies, Inc.
Anti-inflammatory drug cromolyn successfully delayed disease onset and was neuroprotective in a mouse model of ALS Company expects to advance its re-engineered inhaled cromolyn candidate AZT-101...
BrainStorm Announces the Mount Sinai Medical Center as a Progressive MS Phase 2 Clinical Trial Site
November 25, 2019 06:00 ET
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
Cytokinetics Announces Presentation of Additional Analyses From FORTITUDE-ALS at the 18th Annual NEALS Meeting
October 04, 2019 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced additional analyses of FORTITUDE-ALS (Functional Outcomes in a Randomized...
Cytokinetics Announces Additional Results From FORTITUDE-ALS to be Presented at the 18th Annual NEALS Meeting
September 26, 2019 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from FORTITUDE-ALS (Functional Outcomes in...